Echo Therapeutics (ECTE) 1.25 $ECTE
Echo Therapeutics accounting firm quits
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 3:15PM CST
ECTE: 1.25 (-0.07)
Global Continuous Glucose Monitoring System 2014 - 2020
M2 - Fri Dec 12, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/ccxjt3/global_continuous) has announced the addition of the "Global Continuous Glucose Monitoring System 2014 - 2020" report to their offering. Emergence of continuous glucose monitoring systems is a major breakthrough in the glucose monitoring for diabetic patients. Medtronic and Dexcom are the only major players in this industry followed by Abbott in few regions. Companies are focusing more on research and development before introducing their products in the market. CGMS are highly regulated and go through strict tests before being approved. CGM manufacturers have faced competition from Finger based self-monitoring blood glucose devices. SMBG devices are cheaper and easy to use and are easily approved by the authorities. SMBG has more number of players and larger market share. However, CGM systems have been able to make a good market entry in the U.S. and are following the trend in other territories. . CGM system market has seen good growth rates in past three years. Medtronic and Dexcom have introduced new systems which have witnessed lower frequency of errors. The MARD value for new sensors has decreased, new devices need lesser calibrations per day and most of the devices are approved for pediatric use. This has led to 50-60 percent jump in the revenues of some manufacturers. Global Continuous Glucose Monitoring System Market - CGM Market - Real Time Monitoring - Integrated Insulin Pumps - Blood Glucose - Manufacturers - Global Health - IPRO Glucose - MARD - SMBG - Growing Diabetic Population - Type 1 & 2 Diabetes - Nocturnal Hypoglycemia Key Topics Covered: Chapter 1. Executive Summary Chapter 2. Market Overview Chapter 3. Market Determinants Chapter 4. Sector Analysis: Diabetes Care Chapter 5. Cgms Market By Devices Chapter 6. By Application Chapter 7. Competitive Intelligence Chapter 8. Market Share Analysis Chapter 9. Geographical Analysis Chapter 10. Corporate Profile: Benchmark Study - Medtronic Inc. - Dexcom - Abbott - Johnson And Johnson (J&J) (Animas Corp) - Insulet Corp - Tandem Diabetes - Echo Therapeutics For more information visit http://www.researchandmarkets.com/research/cc...continuous
ECTE: 1.25 (-0.07), JNJ: 104.43 (-2.29), PODD: 43.66 (-1.56), MDT: 72.52 (-1.25)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 11:45AM CST
ALOG: 85.14 (-1.54), VBIV: 3.48 (-0.03), PRTK: 29.05 (+1.06), TPLM: 4.06 (-0.18), MIND: 5.92 (+0.17), SSE: 4.58 (-0.12), ALLT: 8.54 (+0.11), EGY: 4.49 (-0.06), GBR: 1.13 (+0.03), ECTE: 1.25 (-0.07), PWE: 2.15 (-0.06), GDP: 3.93 (-0.33), LAYN: 8.22 (+0.46), WRES: 1.32 (+0.03), CALA: 29.85 (+6.65), AKER: 3.22 (+0.05), CVEO: 7.81 (-0.15), CNIT: 4.30 (+0.09), CYRN: 1.80 (-0.16), CRK: 5.26 (-0.49)
Echo Therapeutics' CFO resigns after four months on job
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 3:45PM CST
ECTE: 1.25 (-0.07)
Echo Therapeutics Q3 results
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 5:49AM CST
ECTE: 1.25 (-0.07)
Echo Therapeutics reports Q3 loss
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 5:09PM CST
ECTE: 1.25 (-0.07)
Echo Therapeutics Announces Third Quarter 2014 Financial Results
PR Newswire - Wed Nov 19, 5:00PM CST
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company, today announced its financial results for the quarter ended September 30, 2014. Echo's Quarterly Report on Form 10-Q, when filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com.
ECTE: 1.25 (-0.07)
Research and Markets: Mycosis Fungoides Therapeutics Pipeline Review, H2 2014 Report Featuring Sanofi, Seattle Genetics, Inc, Echo Therapeutics, Inc. & Actelion Ltd
Business Wire - Thu Nov 06, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mlg9h9/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2014" report to their offering.
ECTE: 1.25 (-0.07), SGEN: 32.25 (-1.49)
Mycosis Fungoides Therapeutics Pipeline Review, H2 2014 Report Featuring Sanofi, Seattle Genetics, Inc, Echo Therapeutics, Inc. & Actelion Ltd
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/n96mgn/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mycosis Fungoides, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mycosis Fungoides and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - Seattle Genetics, Inc. - Echo Therapeutics, Inc. - Actelion Ltd Drug Profiles - brentuximab vedotin - mechlorethamine hydrochloride - alemtuzumab - methotrexate - NSC-678515 - CIGB-128 For more information visit http://www.researchandmarkets.com/research/n9..._fungoides
ECTE: 1.25 (-0.07), SGEN: 32.25 (-1.49)
Echo Therapeutics to Present Positive Clinical Trial Results at the 14th Annual Diabetes Technology Meeting
PR Newswire - Mon Nov 03, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"
, a medical device company, will present its most recently completed clinical study of its non-invasive Symphony® Continuous Glucose Monitoring (CGM) System at the 14th Annual Diabetes Technology Meeting, November 6th to 8th in Bethesda, MD.
ECTE: 1.25 (-0.07)
Platinum Comments On Recent Statements Purportedly Made By Echo Therapeutics
PR Newswire - Mon Oct 06, 8:26AM CDT
An affiliate of Platinum Management (NY) LLC ("Platinum" , the largest stockholder of Echo Therapeutics, Inc. ("Echo" or the "Company" (NASDAQ: ECTE) owning approximately 30% of Echo's outstanding Common Stock on a fully converted basis, today commented on recent statements made, Platinum can only assume, by William Grieco, Vincent Enright and James Smith (the "Lingering Directors" , purportedly on behalf of Echo.
ECTE: 1.25 (-0.07)
Echo Therapeutics Comments On Special Meeting Proxy Contest Threatened By Platinum Management (NY) LLC
PR Newswire - Mon Oct 06, 8:10AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company, today commented on the special meeting proxy contest that has been recently threatened by Platinum Management (NY) LLC and its affiliates in their latest attempt to force off the Echo Board the only independent board members that were not designated or nominated by Platinum.
ECTE: 1.25 (-0.07)
Echo Therapeutics Engages PricewaterhouseCoopers' Restructuring Practice to Explore Financial and Strategic Alternatives
PR Newswire - Thu Oct 02, 3:59PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company, today announced that the Company has retained PricewaterhouseCoopers LLP's Restructuring and Recovery Services Practice (PwC) as a financial and restructuring consultant to assist the Company in exploring financial and strategic alternatives that could sufficiently address its liquidity needs and allow it to resume operations. Such financial and strategic alternatives could include, but are not limited to, a sale of intellectual property and other assets, a merger, other business combination, a capital transaction and/or a voluntary petition for reorganization or liquidation pursuant to the U.S. Bankruptcy Code.
ECTE: 1.25 (-0.07)
Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg
PR Newswire - Thu Oct 02, 6:50AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company, today commented on the recent unauthorized public statements relating to Echo that have been made by Michael Goldberg M.D. and Shepard M. Goldberg, two members of the Echo Board of Directors that were either designated or nominated to the Echo Board by an affiliate of Platinum Management (NY) LLC. In recent weeks, the Goldbergs have engaged in numerous unauthorized public communications targeted at Echo stockholders, the trading markets and the media. These have included an unauthorized public "investor" conference call during which the Goldbergs made a presentation relating to Echo, unauthorized press releases discussing Echo and other unauthorized statements by which the Goldbergs have sought to relay to Echo stockholders information relating to Echo, its prospects and its financing and strategic alternatives.
ECTE: 1.25 (-0.07)
Echo Therapeutics Suspends Operations on Cash Concerns - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:45PM CDT
Following the company's decision, shares of Echo Therapeutics, Inc. (ECTE) crashed a substantial 32.5% to finally close at $0.77 till the last trading session.
ECTE: 1.25 (-0.07), ATEC: 1.28 (-0.01), EW: 128.87 (-3.20), ERB: 2.85 (unch)
Platinum Management (NY) LLC Calls for a Special Meeting of Stockholders at Echo Therapeutics, Inc.
PR Newswire - Mon Sep 29, 2:49PM CDT
Platinum Management (NY) LLC ("Platinum" , the largest stockholder of Echo Therapeutics, Inc. ("Echo" or the "Company" (NASDAQ: ECTE) together with its affiliates owning approximately 30% of Echo's outstanding Common Stock on a fully converted basis, today announced that it intends to file the documents required to demand a Special Meeting of stockholders of Echo to remove, for cause, Directors William Grieco, Vincent Enright and James Smith. (collectively, the "Lingering Directors"
ECTE: 1.25 (-0.07)
Platinum Management and Newly Elected Board Members Unveil New Financing Plan for Echo Therapeutics
GlobeNewswire - Wed Sep 24, 8:21AM CDT
Michael Goldberg M.D. and Shepard M. Goldberg, both recently elected board members of Echo Therapeutics (Nasdaq:ECTE), have expressed alarm at the press release issued by the Company yesterday evening, September 23. Dr. Goldberg and Mr. Goldberg believe the release, which they had not seen prior to its publication, contains numerous errors, misstatements and is not an accurate reflection of the current state of affairs at Echo Therapeutics. In fact, Dr. Goldberg and Mr. Goldberg, in an effort to salvage the company, have negotiated a financing deal that meets and exceeds the terms stated as necessary in the release issued by the opposing members of Echo's board. The proposed plan will allow Echo to continue operations and to reach key valuation events prior to requiring additional capital. The plan set forth by Dr. and Mr. Goldberg has the added benefit of having the support of Echo's former key technical staff members who were terminated yesterday but who remain committed to the company.
ECTE: 1.25 (-0.07)
Market Maker Surveillance Report. RITT, JRJC, UQM, GLMD, SINO, ECTE, Winning Stocks With Lowest Price Friction For Tuesday, September 23rd 2014
M2 - Wed Sep 24, 3:42AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4582 companies with "abnormal" market making, 1424 companies with positive Friction Factors and 3854 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Rit Technologies Ltd (NASDAQ:RITT), China Finance Online Co Ltd (NASDAQ:JRJC), UQM Technologies Inc (NYSE:UQM), GOLD MEDAL RES LTD (NASDAQ:GLMD), Sino-Global Shipping America Ltd (NASDAQ:SINO), Echo Therapeutics Inc (NASDAQ:ECTE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ECTE: 1.25 (-0.07), JRJC: 7.62 (-0.31), GLMD: 4.90 (-0.10), UQM: 0.91 (+0.01), RITT: 1.10 (unch), SINO: 1.66 (+0.02)
Echo Therapeutics Suspends Operations To Conserve Liquidity
PR Newswire - Tue Sep 23, 5:40PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company, today announced that, as it believes that its current liquidity is insufficient to fund its needs beyond September 30, 2014, it has suspended its product development, research, manufacturing and clinical programs and operations to conserve its liquidity and capital resources.
ECTE: 1.25 (-0.07)
Market Maker Surveillance Report. CNQR, CNET, MGPI, INUV, ECTE, DSLV, Winning Stocks With Lowest Price Friction For Friday, September 19th 2014
M2 - Mon Sep 22, 3:07AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4914 companies with "abnormal" market making, 1880 companies with positive Friction Factors and 3143 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Friday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Concur Technologies Inc (NASDAQ:CNQR), Chinanet Online Holdings Inc (NASDAQ:CNET), MGP Ingredients Inc (NASDAQ:MGPI), Inuvo Inc (NYSE:INUV), Echo Therapeutics Inc (NASDAQ:ECTE), (NYSE
SLV). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ECTE: 1.25 (-0.07), CNQR: 128.78 (-0.02), INUV: 1.27 (+0.05), MGPI: 15.78 (-0.62), DSLV: 59.76 (+0.37), CNET: 1.12 (-0.16)
Echo Therapeutics accounting firm quits
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 3:15PM CST
ECTE: 1.25 (-0.07)
Global Continuous Glucose Monitoring System 2014 - 2020
M2 - Fri Dec 12, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/ccxjt3/global_continuous) has announced the addition of the "Global Continuous Glucose Monitoring System 2014 - 2020" report to their offering. Emergence of continuous glucose monitoring systems is a major breakthrough in the glucose monitoring for diabetic patients. Medtronic and Dexcom are the only major players in this industry followed by Abbott in few regions. Companies are focusing more on research and development before introducing their products in the market. CGMS are highly regulated and go through strict tests before being approved. CGM manufacturers have faced competition from Finger based self-monitoring blood glucose devices. SMBG devices are cheaper and easy to use and are easily approved by the authorities. SMBG has more number of players and larger market share. However, CGM systems have been able to make a good market entry in the U.S. and are following the trend in other territories. . CGM system market has seen good growth rates in past three years. Medtronic and Dexcom have introduced new systems which have witnessed lower frequency of errors. The MARD value for new sensors has decreased, new devices need lesser calibrations per day and most of the devices are approved for pediatric use. This has led to 50-60 percent jump in the revenues of some manufacturers. Global Continuous Glucose Monitoring System Market - CGM Market - Real Time Monitoring - Integrated Insulin Pumps - Blood Glucose - Manufacturers - Global Health - IPRO Glucose - MARD - SMBG - Growing Diabetic Population - Type 1 & 2 Diabetes - Nocturnal Hypoglycemia Key Topics Covered: Chapter 1. Executive Summary Chapter 2. Market Overview Chapter 3. Market Determinants Chapter 4. Sector Analysis: Diabetes Care Chapter 5. Cgms Market By Devices Chapter 6. By Application Chapter 7. Competitive Intelligence Chapter 8. Market Share Analysis Chapter 9. Geographical Analysis Chapter 10. Corporate Profile: Benchmark Study - Medtronic Inc. - Dexcom - Abbott - Johnson And Johnson (J&J) (Animas Corp) - Insulet Corp - Tandem Diabetes - Echo Therapeutics For more information visit http://www.researchandmarkets.com/research/cc...continuous
ECTE: 1.25 (-0.07), JNJ: 104.43 (-2.29), PODD: 43.66 (-1.56), MDT: 72.52 (-1.25)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 11:45AM CST
ALOG: 85.14 (-1.54), VBIV: 3.48 (-0.03), PRTK: 29.05 (+1.06), TPLM: 4.06 (-0.18), MIND: 5.92 (+0.17), SSE: 4.58 (-0.12), ALLT: 8.54 (+0.11), EGY: 4.49 (-0.06), GBR: 1.13 (+0.03), ECTE: 1.25 (-0.07), PWE: 2.15 (-0.06), GDP: 3.93 (-0.33), LAYN: 8.22 (+0.46), WRES: 1.32 (+0.03), CALA: 29.85 (+6.65), AKER: 3.22 (+0.05), CVEO: 7.81 (-0.15), CNIT: 4.30 (+0.09), CYRN: 1.80 (-0.16), CRK: 5.26 (-0.49)
Echo Therapeutics' CFO resigns after four months on job
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 3:45PM CST
ECTE: 1.25 (-0.07)
Echo Therapeutics Q3 results
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 5:49AM CST
ECTE: 1.25 (-0.07)
Echo Therapeutics reports Q3 loss
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 5:09PM CST
ECTE: 1.25 (-0.07)
Echo Therapeutics Announces Third Quarter 2014 Financial Results
PR Newswire - Wed Nov 19, 5:00PM CST
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company, today announced its financial results for the quarter ended September 30, 2014. Echo's Quarterly Report on Form 10-Q, when filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com.
ECTE: 1.25 (-0.07)
Research and Markets: Mycosis Fungoides Therapeutics Pipeline Review, H2 2014 Report Featuring Sanofi, Seattle Genetics, Inc, Echo Therapeutics, Inc. & Actelion Ltd
Business Wire - Thu Nov 06, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mlg9h9/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2014" report to their offering.
ECTE: 1.25 (-0.07), SGEN: 32.25 (-1.49)
Mycosis Fungoides Therapeutics Pipeline Review, H2 2014 Report Featuring Sanofi, Seattle Genetics, Inc, Echo Therapeutics, Inc. & Actelion Ltd
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/n96mgn/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mycosis Fungoides, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mycosis Fungoides and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - Seattle Genetics, Inc. - Echo Therapeutics, Inc. - Actelion Ltd Drug Profiles - brentuximab vedotin - mechlorethamine hydrochloride - alemtuzumab - methotrexate - NSC-678515 - CIGB-128 For more information visit http://www.researchandmarkets.com/research/n9..._fungoides
ECTE: 1.25 (-0.07), SGEN: 32.25 (-1.49)
Echo Therapeutics to Present Positive Clinical Trial Results at the 14th Annual Diabetes Technology Meeting
PR Newswire - Mon Nov 03, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"
, a medical device company, will present its most recently completed clinical study of its non-invasive Symphony® Continuous Glucose Monitoring (CGM) System at the 14th Annual Diabetes Technology Meeting, November 6th to 8th in Bethesda, MD. ECTE: 1.25 (-0.07)
Platinum Comments On Recent Statements Purportedly Made By Echo Therapeutics
PR Newswire - Mon Oct 06, 8:26AM CDT
An affiliate of Platinum Management (NY) LLC ("Platinum"
, the largest stockholder of Echo Therapeutics, Inc. ("Echo" or the "Company" (NASDAQ: ECTE) owning approximately 30% of Echo's outstanding Common Stock on a fully converted basis, today commented on recent statements made, Platinum can only assume, by William Grieco, Vincent Enright and James Smith (the "Lingering Directors" , purportedly on behalf of Echo. ECTE: 1.25 (-0.07)
Echo Therapeutics Comments On Special Meeting Proxy Contest Threatened By Platinum Management (NY) LLC
PR Newswire - Mon Oct 06, 8:10AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company, today commented on the special meeting proxy contest that has been recently threatened by Platinum Management (NY) LLC and its affiliates in their latest attempt to force off the Echo Board the only independent board members that were not designated or nominated by Platinum.
ECTE: 1.25 (-0.07)
Echo Therapeutics Engages PricewaterhouseCoopers' Restructuring Practice to Explore Financial and Strategic Alternatives
PR Newswire - Thu Oct 02, 3:59PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company, today announced that the Company has retained PricewaterhouseCoopers LLP's Restructuring and Recovery Services Practice (PwC) as a financial and restructuring consultant to assist the Company in exploring financial and strategic alternatives that could sufficiently address its liquidity needs and allow it to resume operations. Such financial and strategic alternatives could include, but are not limited to, a sale of intellectual property and other assets, a merger, other business combination, a capital transaction and/or a voluntary petition for reorganization or liquidation pursuant to the U.S. Bankruptcy Code.
ECTE: 1.25 (-0.07)
Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg
PR Newswire - Thu Oct 02, 6:50AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company, today commented on the recent unauthorized public statements relating to Echo that have been made by Michael Goldberg M.D. and Shepard M. Goldberg, two members of the Echo Board of Directors that were either designated or nominated to the Echo Board by an affiliate of Platinum Management (NY) LLC. In recent weeks, the Goldbergs have engaged in numerous unauthorized public communications targeted at Echo stockholders, the trading markets and the media. These have included an unauthorized public "investor" conference call during which the Goldbergs made a presentation relating to Echo, unauthorized press releases discussing Echo and other unauthorized statements by which the Goldbergs have sought to relay to Echo stockholders information relating to Echo, its prospects and its financing and strategic alternatives.
ECTE: 1.25 (-0.07)
Echo Therapeutics Suspends Operations on Cash Concerns - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:45PM CDT
Following the company's decision, shares of Echo Therapeutics, Inc. (ECTE) crashed a substantial 32.5% to finally close at $0.77 till the last trading session.
ECTE: 1.25 (-0.07), ATEC: 1.28 (-0.01), EW: 128.87 (-3.20), ERB: 2.85 (unch)
Platinum Management (NY) LLC Calls for a Special Meeting of Stockholders at Echo Therapeutics, Inc.
PR Newswire - Mon Sep 29, 2:49PM CDT
Platinum Management (NY) LLC ("Platinum"
, the largest stockholder of Echo Therapeutics, Inc. ("Echo" or the "Company" (NASDAQ: ECTE) together with its affiliates owning approximately 30% of Echo's outstanding Common Stock on a fully converted basis, today announced that it intends to file the documents required to demand a Special Meeting of stockholders of Echo to remove, for cause, Directors William Grieco, Vincent Enright and James Smith. (collectively, the "Lingering Directors" ECTE: 1.25 (-0.07)
Platinum Management and Newly Elected Board Members Unveil New Financing Plan for Echo Therapeutics
GlobeNewswire - Wed Sep 24, 8:21AM CDT
Michael Goldberg M.D. and Shepard M. Goldberg, both recently elected board members of Echo Therapeutics (Nasdaq:ECTE), have expressed alarm at the press release issued by the Company yesterday evening, September 23. Dr. Goldberg and Mr. Goldberg believe the release, which they had not seen prior to its publication, contains numerous errors, misstatements and is not an accurate reflection of the current state of affairs at Echo Therapeutics. In fact, Dr. Goldberg and Mr. Goldberg, in an effort to salvage the company, have negotiated a financing deal that meets and exceeds the terms stated as necessary in the release issued by the opposing members of Echo's board. The proposed plan will allow Echo to continue operations and to reach key valuation events prior to requiring additional capital. The plan set forth by Dr. and Mr. Goldberg has the added benefit of having the support of Echo's former key technical staff members who were terminated yesterday but who remain committed to the company.
ECTE: 1.25 (-0.07)
Market Maker Surveillance Report. RITT, JRJC, UQM, GLMD, SINO, ECTE, Winning Stocks With Lowest Price Friction For Tuesday, September 23rd 2014
M2 - Wed Sep 24, 3:42AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4582 companies with "abnormal" market making, 1424 companies with positive Friction Factors and 3854 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Rit Technologies Ltd (NASDAQ:RITT), China Finance Online Co Ltd (NASDAQ:JRJC), UQM Technologies Inc (NYSE:UQM), GOLD MEDAL RES LTD (NASDAQ:GLMD), Sino-Global Shipping America Ltd (NASDAQ:SINO), Echo Therapeutics Inc (NASDAQ:ECTE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ECTE: 1.25 (-0.07), JRJC: 7.62 (-0.31), GLMD: 4.90 (-0.10), UQM: 0.91 (+0.01), RITT: 1.10 (unch), SINO: 1.66 (+0.02)
Echo Therapeutics Suspends Operations To Conserve Liquidity
PR Newswire - Tue Sep 23, 5:40PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company, today announced that, as it believes that its current liquidity is insufficient to fund its needs beyond September 30, 2014, it has suspended its product development, research, manufacturing and clinical programs and operations to conserve its liquidity and capital resources.
ECTE: 1.25 (-0.07)
Market Maker Surveillance Report. CNQR, CNET, MGPI, INUV, ECTE, DSLV, Winning Stocks With Lowest Price Friction For Friday, September 19th 2014
M2 - Mon Sep 22, 3:07AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4914 companies with "abnormal" market making, 1880 companies with positive Friction Factors and 3143 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Friday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Concur Technologies Inc (NASDAQ:CNQR), Chinanet Online Holdings Inc (NASDAQ:CNET), MGP Ingredients Inc (NASDAQ:MGPI), Inuvo Inc (NYSE:INUV), Echo Therapeutics Inc (NASDAQ:ECTE), (NYSE
SLV). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . ECTE: 1.25 (-0.07), CNQR: 128.78 (-0.02), INUV: 1.27 (+0.05), MGPI: 15.78 (-0.62), DSLV: 59.76 (+0.37), CNET: 1.12 (-0.16)
